Quarterly ResultMay 13, 2026, 05:07 PM
ClearPoint Neuro Q1 Revenue +43% to $12.1M; Net Loss $(9.55)M
AI Summary
ClearPoint Neuro reported a 43% increase in total revenue to $12.1 million for the first quarter of 2026, primarily driven by a 66% rise in product revenue. Despite strong top-line growth, the company's net loss widened to $9.55 million, or $(0.32) per share, compared to a net loss of $6.03 million in the prior year. Cash and cash equivalents decreased to $35.59 million, with net cash used in operations increasing to $7.97 million. The company's acquisition of IRRAS in November 2025 expanded its neurocritical care portfolio, and management confirmed sufficient liquidity for the next twelve months.
Key Highlights
- Total revenue increased 43% to $12.1 million for Q1 2026, up from $8.48 million in Q1 2025.
- Product revenue grew 66% to $8.8 million in Q1 2026, compared to $5.29 million in Q1 2025.
- Net loss widened to $9.55 million, or $(0.32) per share, for Q1 2026.
- Cash and cash equivalents decreased to $35.59 million as of March 31, 2026, from $45.92 million at Dec 31, 2025.
- Net cash used in operating activities was $7.97 million for Q1 2026, compared to $6.17 million in Q1 2025.
- Acquired IRRAS Holdings, Inc. in November 2025 for $5.0 million cash and 1.33 million shares.
- Received $48.1 million from a $105 million note purchase agreement as of March 31, 2026.
- Management affirmed sufficient liquidity to support operations for at least the next 12 months.
Price Impact
More from CLPT